David Hallal

David Hallal

Advisor

Executive Partners

Cambridge Office

David Hallal currently serves as an MPM Advisor and Co-Founder, Chairman and CEO of ElevateBio, an MPM portfolio company that is a cell and gene therapy technology company that powers the design, manufacturing and development of transformative therapies. David is also Executive Chairman of AlloVir (NASDAQ: ALVR), an ElevateBio portfolio company developing innovative allogeneic, off-the-shelf, multi-virus specific T-cell immunotherapies. At ElevateBio and AlloVir, David has raised $1.6B in private and public financings that have led to multiple ongoing Phase 3 clinical trials at AlloVir and growing revenues at ElevateBio with its disruptive technology and manufacturing platform.

David brings more than 30 years of senior executive leadership experience in growing and operating several successful commercial stage biotechnology companies to his advisory role at MPM. He also serves as Chairman of the Board at iTeos Therapeutics (NASDAQ: ITOS), an MPM portfolio company, Chairman of the Board at Scholar Rock (NASDAQ: SRRK), and is Lead Independent Director of the Board of Directors at Seer (NASDAQ: SEER). Across ITOS, SRRK, and SEER, David has supported more than $2B in public and private financings resulting in multiple therapies in Phase 3 and earlier stages of clinical development as well as growing revenues at Seer with its disruptive proteomics platform.

Prior to MPM, he spent nearly 11 years at Alexion Pharmaceuticals where he played a central  role as CEO, Chief Operating Officer and Chief Commercial Officer in transforming the then pre-commercial company into a successful commercial company operating in 50 countries with greater than $3 billion in annual revenues.. As the CEO of Alexion, he grew revenues and expanded the pipeline from a single-product to a multi-product enterprise which eventually led to Alexion being acquired for $40 billion by Astra Zeneca. Prior to Alexion, from 1988-2006, David held leadership and executive positions at Amgen, Biogen and Eyetech where he was responsible for the commercial launches for multiple first-in-class therapies in hematology, oncology, nephrology, immunology, and ophthalmology.

David received his B.A. in Psychology from the University of New Hampshire.